Herrmann S M, Funke-Kaiser H, Schmidt-Petersen K, Nicaud V, Gautier-Bertrand M, Evans A, Kee F, Arveiler D, Morrison C, Orzechowski H D, Elbaz A, Amarenco P, Cambien F, Paul M
Institute of Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, Benjamin Franklin Medical Center, Freie Universität Berlin, Germany.
Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1538-43. doi: 10.1161/hq0901.095555.
Cathepsin G (CTSG), a serine protease released from activated neutrophils, may cause platelet activation, leading to intravascular thrombosis, thus contributing to cardiovascular and cerebrovascular disease. Applying the candidate gene approach, we screened the 5'-flanking region and the entire coding region of the CTSG gene for genetic variation by using polymerase chain reaction/single-strand conformation polymorphism analysis from 96 patients at high risk for myocardial infarction (MI). We identified 4 polymorphisms in the 5'-flanking region (G-618C, G-315A, C-179T, and C-160T) and 1 polymorphism in the coding region (Asn125Ser) of the gene and genotyped the participants in the Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM Study), a case-control study for MI, and in the Etude du Profil Génétique de l'Infarctus Cérébral (GENIC Study), a case-control study for brain infarction (BI), for all identified genetic variants. The potential in vitro functionality of the 4 variants in the 5'-flanking region was investigated with transient transfection analyses in U937 cells with different allelic promoter constructs by using a luciferase assay. Our in vitro analyses did not reveal any differences for the investigated allelic constructs with respect to promoter activity, and none of the polymorphisms in the 5'-flanking region was associated with the available phenotypes in either study. Allele and genotype distributions of all identified polymorphisms did not globally differ between cases and controls in the ECTIM Study. However, in patients from the ECTIM Study, the Ser125 allele was significantly associated with elevated plasma fibrinogen levels (P=0.006), but this effect was not seen in controls (case-control heterogeneity, P=0.04). There was a significant interaction between CTSG Asn125Ser and the beta-fibrinogen gene polymorphism G-455A on plasma fibrinogen levels (P=0.04). In the GENIC Study, the odds ratio for BI associated with CTSG Ser125 carrying was 1.82 (95% CI 1.16 to 2.84, P=0.008) in patients without a history of cardiovascular or cerebrovascular diseases. Our results indicate that the CTSG Ser125 allele is associated with plasma fibrinogen levels in MI patients from the ECTIM Study and with BI in the GENIC Study. Further studies should be carried out to define the underlying mechanisms.
组织蛋白酶G(CTSG)是一种从活化的中性粒细胞释放的丝氨酸蛋白酶,可能导致血小板活化,进而引发血管内血栓形成,从而促成心血管和脑血管疾病。采用候选基因方法,我们通过聚合酶链反应/单链构象多态性分析,对96例心肌梗死(MI)高危患者的CTSG基因5'侧翼区和整个编码区进行了遗传变异筛查。我们在该基因的5'侧翼区鉴定出4种多态性(G-618C、G-315A、C-179T和C-160T),在编码区鉴定出1种多态性(Asn125Ser),并对心肌梗死病例对照研究“心肌梗死病例对照研究(ECTIM研究)”以及脑梗死病例对照研究“脑梗死基因研究(GENIC研究)”的参与者进行了所有已鉴定遗传变异的基因分型。通过使用荧光素酶测定法,在U937细胞中用不同等位基因启动子构建体进行瞬时转染分析,研究了5'侧翼区4种变异的潜在体外功能。我们的体外分析未发现所研究的等位基因构建体在启动子活性方面有任何差异,并且在两项研究中,5'侧翼区的多态性均与现有表型无关。在ECTIM研究中,所有已鉴定多态性的等位基因和基因型分布在病例组和对照组之间总体上没有差异。然而,在ECTIM研究的患者中,Ser125等位基因与血浆纤维蛋白原水平升高显著相关(P=0.006),但在对照组中未观察到这种效应(病例对照异质性,P=0.04)。CTSG Asn125Ser与β-纤维蛋白原基因多态性G-455A在血浆纤维蛋白原水平上存在显著相互作用(P=0.04)。在GENIC研究中,对于无心血管或脑血管疾病病史的患者,携带CTSG Ser125与脑梗死相关的优势比为1.82(95%CI 1.16至2.84,P=0.008)。我们的结果表明,CTSG Ser125等位基因在ECTIM研究的MI患者中与血浆纤维蛋白原水平相关,在GENIC研究中与脑梗死相关。应开展进一步研究以确定潜在机制。